Investments, Funding & Disinvestment

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.

This approach will help ensure that the local manufacturing of diagnostic imaging equipment remains economically viable and financially sustainable over the coming years.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Antimicrobial resistance (AMR) develops when bacteria, viruses, and fungi evolve to resist medications, making infections harder to treat and increasing the risk of severe illness and death.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

The project will generate between 500 and 700 direct jobs and feature advanced digital infrastructure to ensure operational efficiency, traceability, and robust quality control.

The newly constructed, purpose-built facility is designed to handle high potency drugs, including oncology and hormone products.

The biotechnology market was valued at USD 1.6 trillion in 2020 and is expected to grow at a compound annual growth rate of 14.2%, reaching USD 4.05 trillion by 2035.